Do you want to read an article? Please log in or register.
Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial
Macular Diseases
Related content
COMMENTED
Further Publications
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
JAMA Ophthalmol
Lim TH, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Lee WK, Cheung CMG, Ngah NF, Patalauskaite R, Margaron P, Koh A, EVEREST II Study Group.
doi: 10.1001/jamaophthalmol.2020.2443
Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial
JAMA Ophthalmol.
Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, Ming Cheung GC, Zhang Z, Leal S, Ishibashi T, for the PLANET Investigators
Retinal Diseases
Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial
JAMA Pediatr.
Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, Ehrt O, Aisenbrey S, Roider J, Gerding H, Jandeck C, Smith LEH, Walz JM; Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (CARE-ROP) Study Group
doi: 10.1001/
Cornea and Corneal DiseasesConjunctivitisBlindness and Vision ImpairmentFlammer SyndromeGlaucoma and Ocular PressureLensesMacular DiseasesOcular OncologyRetinal DiseasesSurgery and InterventionUveitisCataractsDry Eye Disease
RANIBIZUMAB WITH OR WITHOUT VERTEPORFIN PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: Predictors of Visual and Anatomical Response in the EVEREST II Study
Retina
Cheung CMG, Tan CS, Patalauskaite R, Margaron P, Lai TYY
doi: 10.1097/IAE.0000000000002902
COMMENTED
Macular Diseases
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
JAMA Ophthalmol
Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM
doi: 10.1001/jamaophthalmol.2020.5053
Macular Diseases
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
JAMA Ophthalmol.
Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Weikert R, Fauser S
doi: 10.1001/jamaophthalmol.
Further Publications
Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: 2-Year Results of the PLANET Study
Am J Ophthalmol.
Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, Gemmy Cheung CM, Zhang Z, Leal S, Ishibashi T, Planet Investigators
doi: 10.1016/j.ajo.
Cornea and Corneal DiseasesConjunctivitisBlindness and Vision ImpairmentFlammer SyndromeGlaucoma and Ocular PressureLensesMacular DiseasesOcular OncologyRetinal DiseasesSurgery and InterventionUveitisCataractsDry Eye Disease
Two different treatment regimens of ranibizumab 0.5 mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study
Acta Ophthalmol
Li X, Zhu Q, Egger A, Chang L, Wolf S, Song Y, Zhang J, Dong F, Xu X, Weisberger A
doi: 10.1111/aos.14588
Retinal Diseases
Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia: A Randomized Clinical Trial
JAMA Ophthalmol.
Fischer MD, Ochakovski GA, Beier B, Seitz IP, Vaheb Y, Kortuem C, Reichel FFL, Kuehlewein L, Kahle NA, Peters T, Girach A, Zrenner E, Ueffing M, MacLaren RE, Bartz-Schmidt KU, Wilhelm B
doi: 10.1001/jamaophthalmol.